Navigation Links
Old and new therapies combine to tackle atherosclerosis
Date:9/15/2008

Fumagillin nanoparticles could be used to further inhibit the development of new vessel treatment in high-risk patients, Lanza says.

"Our past research showed that fumagillin nanoparticles reduced blood vessel formation at the site of arterial plaques in experimental rabbits after one week," says Lanza. "In this study, we tested how long that effect lasts and if it could be extended by statins."

The rabbits used in the study ate a high-fat diet that caused arterial plaques. The researchers detected new blood vessel buildup at the site of plaques by coating nanoparticles that were targeted to neovessels with an MRI contrast agent.

When the rabbits received a single dose of blood-vessel-targeted nanoparticles that also carried fumagillin, the researchers saw that the amount of MRI signal at the sites of plaques decreased about five-fold by the end of one week. But a high MRI signal returned by the fourth week, indicating that plaques were active again.

Because repeated injections of fumagillin nanoparticles is impractical for treating human patients, the researchers looked for a way to extend the initial effectiveness.

Atherosclerotic rabbits that got daily doses of the statin atorvastatin (brand name Lipotor) had no change in plaque angiogenesis measured by MRI. When the statin and the fumagillin nanoparticles were started at the same time, the atorvastatin had no additional benefits over the targeted therapy.

However, when the statin had been given for at least one month prior to the fumagillin treatment, the five-fold reduction in MRI signal due to diminished neovessels was maintained for four weeks.

Lanza says that the results suggest that one or possibly two injections of nanoparticles in patients who are already on statins could lead to a long-term reduction in plaque activity and prolonged plaque stability. The results also illustrate the potential clinical use of MRI molecular imaging with the neovessel-targeted nanoparticle
'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
2. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
3. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
4. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
5. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
6. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
7. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
8. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
9. Organogenesis, Inc. to Develop Regenerative Medicine Therapies for U.S. Military Battlefield Injuries
10. Genomics Likely to Replace Traditional Drug Therapies in Treating CHF
11. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 -- A novel combination of microscopy ... of Energy,s Oak Ridge National Laboratory an unprecedented look ... unusual physical and electrochemical properties. , The research ... affects the surface of a perovskite manganite, a complex ... new avenue to understand surface behavior could benefit researchers ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... Yung-Eun Sung has announced that they have developed ... which can be applied as high performance electrodes ... is both a group leader at the Center ... (IBS) and a professor at the Seoul National ... regards to the development of relative simplicity, scalablity, ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... ... it is a sponsor for this year’s 4th Annual Orthopedic Design & Tradeshow (ODT) ... NEIRP partners and staff will also be available to meet tradeshow attendees at ... region has to offer to the medical device industry . , ...
... 5 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) ... trial evaluating bavituximab in combination with carboplatin and paclitaxel ... Data previously reported from the initial cohort of 21 ... 17 evaluable patients with locally advanced or metastatic NSCLC ...
... Regado Biosciences, a privately held company leading the development ... that David J. Mazzo, Ph.D., President and Chief Executive ... 2009 at the Conrad Hotel in Tokyo, Japan. ... on October 6, 2009. The Conference brings together premier ...
Cached Biology Technology:Northeast Indiana Regional Partnership to Participate in 2009 Orthopedic Design & Technology Conference & Exhibition 2Northeast Indiana Regional Partnership to Participate in 2009 Orthopedic Design & Technology Conference & Exhibition 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009 2
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
(Date:7/24/2014)... has developed a new nanoscale agent for imaging the ... the function and properties of the GI tract in ... of gut diseases. , Illnesses such as ... bowel disease all occur in the intestine and can ... such as diabetes and Parkinson,s. , Until now, ...
(Date:7/24/2014)... have similar counterparts in humans, affect the connections between ... into the hippocampus, an area of the brain that ... creation of memories. The results of the study have ... Brain function depends on the active communication between nerve ... woven together into a dense network where they constantly ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3New imaging agent provides better picture of the gut 2A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4
... from smart phones to SUVs are starting to design ... for an often troublesome life after the consumer, according ... (C&EN), ACS, weekly newsmagazine. The cover story ... product stewardship, an increasingly popular approach to environmental protection ...
... of Standards and Technology (NIST) is working with the ... emergency first responders in the delicate and potentially critical ... project, dubbed "Operation Vigilant Sample," seeks to coordinate training ... federal levels based on newly developed sample collection protocols. ...
... A signaling system in the brain previously shown to ... illness, according to research conducted at Oregon Health & ... is particularly meaningful because it implies that a new ... reverse the inactivity and exhaustion brought on by acute ...
Cached Biology News:Operation Vigilant Sample: First responder training for suspicious powders 2Scientists identify what makes us feel 'bad' when we're sick, how to treat it 2
hnRNP U (H-94)...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
... causing shortages in your laboratory or fellow ... unwanted distractions, problems and delays. ... hard work and endeavour! Bring us your ... market it internationally. We work under ISO ...
... from vaccinia virus is a type I ... negative superhelical turns (also called right- and ... product of the reaction is a covalently ... negative superhelical turns. DNA Topoisomerase I does ...
Biology Products: